Domestic Sales: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Insider Sells $42,315.70 in Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Your Free Report) Minardo John sold 9,910 shares of the company’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $4.27, for a total value of $42,315.70. Following the transaction, the insider now owns 284,661 shares in the company, valued at $1,215,502.47. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC’s website.

Ironwood Pharmaceuticals price performance

Shares of Ironwood Pharmaceuticals opened at $4.32 on Friday. The stock has a market cap of $676.21 million, a price-to-earnings ratio of -0.64 and a beta of 0.52. Ironwood Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $15.70. The company has a fifty day moving average price of $6.10 and a 200 day moving average price of $8.29.

The Wall Street analyst weighs in

Several analysts have issued reports on the company. StockNews.com raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Wells Fargo & Company decreased their price target on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Capital One Financial cut Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $12.00 to $4.00 in a research report on Thursday, August 8th . Finally, Craig Hallum decreased their price target on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.00, according to MarketBeat.com.

Read the latest stock report on IRWD

Ironwood Pharmaceuticals Institutional Marketing

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Ironwood Pharmaceuticals by 21.8% in the first quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company’s stock worth $170,031,000 after acquiring an additional 3,487,821 shares in the last quarter. Pacer Advisors Inc. boosted its stake in Ironwood Pharmaceuticals by 23.6% in the second quarter. Pacer Advisors Inc. now owns 8,907,639 shares of the biotechnology company’s stock worth $58,078,000 after purchasing an additional 1,701,452 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Ironwood Pharmaceuticals by 20.7% in the second quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company’s stock worth $55,889,000 after purchasing an additional 1,472,097 shares during the last quarter. Armistice Capital LLC boosted its stake in Ironwood Pharmaceuticals by 44.4% in the second quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock worth $50,856,000 after purchasing an additional 2,400,000 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in Ironwood Pharmaceuticals by 40.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 4,235,580 shares of the biotechnology company’s stock worth $36,892,000 after purchasing an additional 1,226,377 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

(Get a free report)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase C-type (GC-C) agonist for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation under the name LINZESS in the United States, Mexico, Japan, Saudi Arabia and China. , as well as under the name CONSTELLA in Canada and European countries.

Read more

Get daily news and reviews for Ironwood Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.